Wei Liu

Dr. Wei Liu

Institute of Liver Diseases, Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2022 in Phytomedicine
Verified
Journal Article
Closed access
CZCongcong Zhang
Congcong Zhang
DZDingqi Zhang
Dingqi Zhang
YWYongli Wang
Yongli Wang
LZLinzhang Zhang
Linzhang Zhang
SQShenglan Qi
Shenglan Qi
WLWei Liu
Wei Liu

1 December 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
FXFeipeng Xu
Feipeng Xu
HZHua Zhang
Hua Zhang
JCJiamei Chen
Jiamei Chen
JZJunyi Zhan
Junyi Zhan
PLPing Liu
Ping Liu
YMYongping Mu
Yongping Mu


25 June 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
SLShiyang Li
Shiyang Li
NXNan Xu
Nan Xu
QFQinqin Fang
Qinqin Fang
XCXuemei Cheng
Xuemei Cheng
JCJiamei Chen
Jiamei Chen
WLWei Liu
Wei Liu


1 January 2020 in Pharmaceutical Biology
Verified
Journal Article
Open access
DZDingqi Zhang
Dingqi Zhang
LZLijun Zhang
Lijun Zhang
GCGaofeng Chen
Gaofeng Chen
YXYing Xu
Ying Xu
HYHailin Yang
Hailin Yang
PLPing Liu
Ping Liu
Xiayuxue decoction (XYXD), a traditional Chinese medicine, is used for treating liver disease. However, the potential active constituents and mechanisms are still unclear. To explore the main active fraction extracts, active ingredients and possible mechanisms of XYXD for anti-hepatic fibrosis. Different fractions including ethyl acetate fraction (EF) were prepared from XYXD. These fractions, especially EF, were used to evaluate cell viability, proliferation, cell cycle, cytotoxicity and activation in hepatic stellate cells (HSCs). Liver fibrosis model was established by CCl4 in C57BL/6 mice, and allocated to CCl4 group, XYXD group and EF group with normal mice as control. Further, mitochondrial apoptosis-related proteins of HSCs, destruction and angiogenesis of liver sinusoidal endothelial cells (LSECs) and active ingredients of EF were evaluated. The inhibition of proliferation, increase of S or/and G2/M phase population and suppression of α-SMA and COL-1 expression were obeserved in EF treated-JS1 and -LX2. Liver fibrosis-related indicators were improved by EF similar to XYXD in vivo. EF induced the apoptosis of HSCs in CCl4-induced fibrosis, and inhibited the expression of HSCs apoptosis pathway-related proteins (JNK and p38-MAPKs), and LSECs destruction and angiogenesis. Multiple ingredients (emodin, rhein, aloe-emodin, prunasin) in EF have shown inhibited the activation of JS1. EF was the main active fraction extracts of XYXD, and the underlying mechanisms might relate to induction of HSCs apoptosis. Emodin, rhein, aloe-emodin and prunasin were main active ingredients of EF, which provides a potential drug for the treatment of liver fibrosis.